Prior radiotherapy to the abdomen or pelvis
Prior radiotherapy to the upper abdomen
Prior radiation therapy to the abdomen that would overlap with treatment field
Prior radiation treatment to the upper abdomen
History of prior radiation therapy to the upper abdomen
Previous radiation therapy to the lungs and/or to the upper abdomen
Prior radiotherapy to the upper abdomen or radioembolization of the liver
Prior radiotherapy to the pelvis (or abdomen if para-aortic nodes are involved)
No prior radiotherapy to the upper abdomen
Prior radiation therapy to the upper abdomen or liver
Any prior radiotherapy to the pelvis or abdomen
Prior radiation therapy to the abdomen or pelvis
Prior radiation to the pelvis or abdomen in the metastatic or locally advanced setting.
Metastatic disease outside the confines of the abdomen and pelvis (such as lung, bone, brain)
Prior radiotherapy to the pelvis or abdomen
Received or will receive radiation therapy to the abdomen or pelvis in the week prior to study drug administration and/or during the course of the study
Previous radiotherapy delivered to the upper abdomen.
Any history of metastatic TCC; subjects with suspected malignant lymphadenopathy in the abdomen or pelvis are not allowed
Receipt of radiation to the abdomen for any reason during the planned -day treatment time
Acute abdomen
Ongoing radiation induced diarrhea or constipation or planned radiotherapy to the abdomen or pelvis while on study
Prior radiotherapy to the upper abdomen/liver
Has received or will receive total body irradiation of radiation therapy to the abdomen or pelvis in the week prior to Treatment Day  and/or during the diary reporting period ( hours following initiation of chemotherapy)
Patient must not have undergone major surgery or radiotherapy to the pelvis or abdomen within previous  weeks
Radiotherapy to the abdomen or pelvis within  months of the screening visit
Any and all primary disease sites in the abdomen and pelvis will be allowed
Patients must have no previous radiation to the abdomen